Phibro Animal Health Corp

  • Health Care
  • Biotechnology: Pharmaceutical Preparations
  • www.pahc.com
  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $951.84M
  • PE 55
  • Debt $305.63M
  • Cash $51.84M
  • EV $1.21B
  • FCF $40.67M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$17.41M
EBIT$71.74M
ROE7%
ROA7%
FCF$40.67M
Equity$258.53M
Growth Stability5%
PE54.68
PEG-2
PB3.68
P/FCF23.4
P/S0.91
Price/Cash0.05
Debt/Equity1.18
Debt/FCF7.51
Net Margins3%
Gross Margins31%
Op. Margins7%
Earnings CAGR-17%
Sales Growth YoY13%
Sales Growth QoQ-5%
Sales CAGR4%
FCF CAGR-2%
Equity CAGR22%
Earnings Stability0.54
Earnings Growth YoY-187%
Earnings Growth QoQ828%
Earnings CAGR 5Y-27%
Sales CAGR 5Y6%
FCF CAGR 5Y1%
Equity CAGR 5Y8%
Earnings CAGR 3Y5%
Sales CAGR 3Y5%
FCF CAGR 3Y93%
Equity CAGR 3Y1%
Market Cap$951.84M
Revenue$1.05B
Dividend Yield2%
Payout Ratio112%
Assets$966.29M
Total Debt$305.63M
Cash$51.84M
Shares Outstanding40.5M
EV1.21B
Earnings Score3%
Moat Score76%
Safety Score48%
Final Score42%
Working Capital393.87M
Current Ratio3.23
Shares Growth 3y0%
Equity Growth QoQ1%
Equity Growth YoY-5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the US and other international countries.

SEC Filings

Direct access to Phibro Animal Health Corp (PAHC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-K Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-Q Dec 31
    • 10-Q Sep 30
    • 10-K Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-Q Dec 31
    • 10-Q Sep 30
    • 10-K Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Phibro Animal Health Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Phibro Animal Health Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -17%
Stability 54%
loading chart...

Phibro Animal Health Corp Discounted Cash Flow

Fully customizable DCF calculator online for Phibro Animal Health Corp.

= $350M
012345678910TV
fcf$41M$40M$39M$38M$37M$36M$36M$35M$34M$33M$32M$325M
DCF$36M$32M$29M$25M$23M$20M$18M$16M$14M$13M$125M
Value$350M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years06/201506/201606/201706/201806/201906/202006/202106/202206/202306/2024TTM
Net Margins8%11%8%8%7%4%7%5%3%0%3%
ROA-14%16%15%11%9%9%8%7%5%7%
ROE-91%43%35%25%18%23%19%12%1%7%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years06/201506/201606/201706/201806/201906/202006/202106/202206/202306/2024TTM
Debt over FCF-331.423.314.9814.119.3916.2-83.18-9.37.47.51
Debt over Equity9.793.171.71.391.131.261.291.711.271.341.18
Growth Stability---94%77%55%100%100%71%5%5%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years06/201506/201606/201706/201806/201906/202006/202106/202206/202306/2024CAGR 5Y
Revenue YoY growth-0%2%7%1%-3%4%13%4%4%6%
Earnings YoY growth-37%-22%0%-16%-39%62%-10%-34%-93%-27%
Equity YoY growth-205%67%22%17%-13%27%10%8%-9%8%
FCF YoY growth--98%9K%-34%-66%46%-25%-128%613%-220%1%